Frederic Lombard

CFO

Senior Vice President, Chief Financial Officer

Insider activity · 24 months1 buy0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 1 buy · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (1 ops.)

€80k

▼ Sales (0 ops.)

—

Latest filing published 15 Jan 2026 for Innate Pharma, €80k. Read the official filing

Filing timeline

BuySale

Frederic Lombard

Insider track record

Disclosed buys

Disclosed sells

Signal history

No signal scores available.

Closed purchases

Market purchases

Not enough history yet: 1 closed purchase, at least 2 are needed.

Purchases by company

Innate Pharma 1 purchase · last 15 Jan 2026

Since each purchase

Innate Pharma
Filed 15 Jan 2026 · 275 days ago · €80k
-16.4%
Entry €1.50 · Close 13 Oct 2026 €1.25

Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.

Frederic Lombard: trading record in brief

Frederic Lombard, listed as senior executive, appears in our data through filings on Innate Pharma shares, published by AMF. Between 31 December 2024 and 31 December 2025, the trades on record add up to 2 filings.

Every open-market trade on record is a purchase: 1 purchase worth €80k, and no sale. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Outside the open market, there are 1 share grant. 2026 to date brings 1 purchase and no sales.

Most recently, on 15 January 2026, the filings show an open-market purchase worth €80k in Innate Pharma. Every figure here comes from the filings published by AMF and describes the past, not future prices; it is not investment advice.